At a glance
TIMELINE
1 May 2023
to 30 April 2027
FUNDER
European Union,
UKRI and SERI
COORDINATOR
European Vaccine Initiative (EVI)
FUNDING
€10 Million
Protecting and Enhancing Lives
We believe that our work will not only protect lives but also enhance them. By eliminating malaria, we can improve the quality of life for millions of people around the world.
Our Research Approach
UltiMalVax is using cutting-edge research techniques to develop a vaccine for malaria eradication. Our approach builds on the recent success of R21/Matrix-M™ malaria vaccine and aims to take it to the next level.
Our mission is to develop a vaccine that can eliminate malaria once and for all. We are committed to making a difference in the world.
The UltiMalVax Consortium
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
University of Oxford –Project number: 10079577; NeoVac LTD – Project number 10079247; SpyBiotech LTD - project number 10115196
Vaccine Formulation Institute - The grant number is REF-1131-52304 / SERI No. 23.00184.
NEWSLETTER
© 2024 by European Vaccine Initiative